Dr. Michael Slade joined the Department of Medicine in the Division of Oncology as an Assistant Professor as of July 2023. Dr. Slade did his undergraduate studies at the University of Georgia, where he graduated with a B.A. in Philosophy in 2011. He subsequently matriculated at Washington University School of Medicine in Saint Louis. While enrolled, he also completed a Master of Science in Clinical Investigation degree and received the Richard S. Brookings Medical School Prize on graduation in 2017. He subsequently matched at the Barnes-Jewish Hospital/Washington University School of Medicine Consortium for his internal medicine residency. He continued his training at Washington University in the Hematology/Oncology Fellowship program, where he served as a chief fellow.
Dr. Slade’s current research is focused on cellular immunotherapy and plasma cell dyscrasias, including multiple myeloma and its precusor states. His laboratory-based research is focused on understanding mechanisms of chimeric antigen receptor (CAR) T cell failure in patients with multiple myeloma, including tumor evolution, modulation of the immune microenvironment and CAR T cell exhaustion. His clinical research is focused on the role of autologous stem cell transplant in multiple myeloma and on advanced methods of disease monitoring following myeloma treatment, including ultra-sensitive next generation sequencing, flow cytometry and mass spectrometry, and the impact of measurable residual disease (MRD) on subsequent treatment and clinical outcomes. He also enjoys working with medical students and residents, with a focus on evidence-based medicine and scientific writing. He currently serves as clinical and translational investigator in the Division of Oncology.